Table 1.
Patient characteristics, CAR T-cell treatment, and response of the entire cohort and subgroups separated by the presence of CHIP before CAR T-cell therapy
| Variable | All patients (N = 32) | CHIP group (n = 11) | Non-CHIP group (n = 21) | P |
|---|---|---|---|---|
| Sex | 1.00 | |||
| Male | 19/32 (59) | 7/11 (64) | 12/21 (57) | |
| Female | 13/32 (41) | 4/11 (36) | 9/21 (43) | |
| Age, median (range), y | 62 (37-82) | 69 (56-82) | 58 (37-77) | .01 |
| IPI, median | 2 | 2 | 3 | .20 |
| Prior lines of therapy, median (range), n | 4 (2-6) | 3 (2-6) | 4 (2-6) | .36 |
| Remission before CAR T-cell treatment | .11 | |||
| CR | 2/32 (6) | 2/11 (18) | 0/21 (0) | |
| PR | 11/32 (34) | 5/11 (46) | 6/21 (28) | |
| SD | 6/32 (19) | 1/11 (9) | 5/21 (24) | |
| PD | 13/32 (41) | 3/11 (27) | 10/21 (48) | |
| CAR T-cell product | .35 | |||
| Axicabtagene ciloleucel | 20/32 (62) | 5/11 (45) | 15/21 (71) | |
| Tisagenlecleucel | 8/32 (25) | 4/11 (36) | 4/21 (19) | |
| Other | 4/32 (13) | 2/11 (19) | 2/21 (10) | |
| CRS maximum * | .37 | |||
| 0 | 5/32 (16) | 3/11 (27) | 2/21 (10) | |
| 1 | 12/32 (38) | 5/11 (45) | 7/21 (33) | |
| 2 | 11/32 (34) | 2/11 (19) | 9/21 (43) | |
| 3 | 4/32 (12) | 1/11 (9) | 3/21 (14) | |
| 4 | 0/32 (0) | 0/11 (0) | 0/21 (0) | |
| ICANS, maximum * | .58 | |||
| 0 | 17/32 (53) | 8/11 (73) | 9/21 (43) | |
| 1 | 6/32 (19) | 1/11 (9) | 5/21 (24) | |
| 2 | 4/32 (12) | 1/11 (9) | 3/21 (14) | |
| 3 | 1/32 (4) | 0/11 (0) | 1/21 (5) | |
| 4 | 4/32 (12) | 1/11 (9) | 3/21 (14) | |
| Use of tocilizumab | 22/32 (69) | 6/11 (55) | 16/21 (76) | .39 |
| Use of steroids | 15/32 (47) | 3/11 (27) | 12/21 (57) | .22 |
| Transfusion support after day +28 | ||||
| Red blood cells | 18/30 (60) | 3/10 (30) | 15/20 (75) | .05 |
| Platelets | 19/29 (66) | 3/9 (33) | 16/20 (80) | .04 |
| Best response to CAR T-cell treatment† | .30 | |||
| CR | 9/31 (29) | 5/11 (45) | 4/20 (20) | |
| PR | 17/31 (55) | 5/11 (45) | 12/20 (60) | |
| SD | 3/31 (10) | 0/11 (0) | 3/20 (15) | |
| PD | 2/31 (6) | 1/11 (9) | 1/20 (5) | |
| Response at last follow-up† | .36 | |||
| CR | 5/31 (16) | 3/11 (27) | 2/20 (10) | |
| PR | 9/31 (29) | 4/11 (36) | 5/20 (25) | |
| SD | 2/31 (6) | 0/11 (0) | 2/20 (10) | |
| PD | 15/31 (48) | 4/11 (36) | 11/20 (55) | |
| Death after CAR T-cell treatment | 11/32 (34) | 0/11 (0) | 11/21 (5) | .01 |
Unless otherwise noted, data are n/N (%).
CR, complete response; IPI, International Prognostic Index; PD, progressive disease; PR, partial remission; SD, stable disease.
*
Assessment according to the American Society for Transplantation and Cellular Therapy grading system.19
†
Response was evaluated according to Lugano criteria.